Penumbra, Inc. Aktie News

NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.

MILWAUKEE, Jan. 15, 2026 /PRNewswire/ -- Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Boston Scientific. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

The cash-and-stock acquisition values Penumbra at $374 a share.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock is fair to Penumbra shareholders. Halper Sadeh encourages Penumbra shareholders to click here to learn more about their legal rights and options or contact...

Penumbra's stock was up about 14% after the deal was announced Thursday morning.

Boston Scientific will buy Penumbra for $14.5 billion, or $374 a share, expanding its cardiovascular reach. Penumbra stock jumped.

Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.